Accelerated Breakdown of Phosphatidylcholine and Phosphatidylethanolamine Is a Predominant Brain Metabolic Defect in Alzheimer’s Disease
Jan Krzysztof Blusztajn, Barbara E. Slack
Abstract
Numerous studies have demonstrated defects in multiple metabolic pathways in Alzheimer's disease (AD), detected in autopsy brains and in the cerebrospinal fluid in vivo. However, until the advent of techniques capable of measuring thousands of metabolites in a single sample, it has not been possible to rank the relative magnitude of these abnormalities. A recent study provides evidence that the abnormal turnover of the brain's most abundant phospholipids: phosphatidylcholine and phosphatidylethanolamine, constitutes a major metabolic pathology in AD. We place this observation in a historical context and discuss the implications of a central role for phospholipid metabolism in AD pathogenesis.
Topics & Concepts
PhosphatidylethanolaminePhosphatidylcholineContext (archaeology)DiseasePhospholipidCerebrospinal fluidPathogenesisMetabolic pathwayBiologyPathologyAutopsyAlzheimer's diseaseMetabolismNeuroscienceMedicineBiochemistryPaleontologyMembraneAlzheimer's disease research and treatmentsMetabolomics and Mass Spectrometry StudiesMetabolism and Genetic Disorders